Zoetis has faced significant headwinds over the past 30 days despite isolated positive catalysts, with the stock trading 45% below estimated fair value amid mounting fundamental concerns. The dominant narrative centers on demand softening in pet care and a material guidance cut issued in early August that signaled management's reassessment of operational momentum. However, the FDA's Emergency Use Authorization for Simparica TRIO to treat New World screwworm in dogs represents a meaningful regulatory win that expands an existing franchise product's therapeutic scope. The proposed Neogen merger has encountered antitrust scrutiny from Australian regulators, introducing material execution risk to the transaction. Within the broader animal health sector, weak consumer response to strategic initiatives and sector-wide saturation concerns have pressured valuations. Contrarian investors view current weakness as cyclical rather than structural, positioning ZTS as a potential entry point. Forward momentum hinges on demonstrating demand stabilization, successful regulatory navigation of the Neogen deal, and validation that recent guidance cuts represent a trough rather than the beginning of sustained deterioration in market conditions.